Halozyme Therapeutics announces completion of public offering and underwriters' option
Halozyme Therapeutics announced completion of its underwritten public offering of 11,500,000 shares of its common stock. The offering included 1,500,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. Net proceeds were $135 million. May 24, 2017